Page last updated: 2024-10-15

leucinostatin a

Description

leucinostatin A: isolated from Penicillium lilacinum; A 20668 A,B,& C are polypeptide antibiotics that inhibit phosphorylation of ADP, Mg ATPase; RN given refers to leucinostatin A [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133612155
MeSH IDM0051975

Synonyms (2)

Synonym
76600-38-9
leucinostatin a

Research Excerpts

Overview

Leucinostatin A (Leu-A) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Its employment is limited due its toxicity.

ExcerptReference
"Leucinostatin A (Leu-A) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans; nevertheless, its employment is limited due its toxicity. "( Leucinostatin-A loaded nanospheres: characterization and in vivo toxicity and efficacy evaluation.
Blasi, P; Giovagnoli, S; Perioli, L; Ricci, M; Rossi, C; Vescovi, C, 2004
)

Toxicity

ExcerptReference
" Acute toxicity showed that the LD50 was increased more than 18-fold and the study on systemic candidiasis models revealed high effectiveness of the NS in reducing either the growth of fungal colonies in infected mice liver or in the mortality index."( Leucinostatin-A loaded nanospheres: characterization and in vivo toxicity and efficacy evaluation.
Blasi, P; Giovagnoli, S; Perioli, L; Ricci, M; Rossi, C; Vescovi, C, 2004
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (34.29)18.7374
1990's6 (17.14)18.2507
2000's4 (11.43)29.6817
2010's8 (22.86)24.3611
2020's5 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]